Singapore markets close in 1 hour 58 minutes

Vanda Pharmaceuticals Inc. (0LKB.L)

LSE - LSE Delayed Price. Currency in USD
Add to watchlist
4.4987-0.0563 (-1.24%)
At close: 04:24PM GMT

Vanda Pharmaceuticals Inc.

2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC 20037
United States
202 734 3400
https://www.vandapharma.com

Sector(s)
Industry
Full-time employees203

Key executives

NameTitlePayExercisedYear born
Dr. Mihael H. Polymeropoulos M.D.Founder, President, CEO & Chairman of The Board1.51M1.12M1960
Mr. Kevin Patrick MoranSenior VP, CFO & Treasurer660.22k56.15k1985
Mr. Timothy WilliamsSenior VP, General Counsel & Secretary724.38kN/A1976
Mr. Joakim WijkstromSenior VP & Chief Marketing Officer836.36kN/A1966
Mr. Gunther BirznieksSenior Vice President of Business Development690.83k9.25k1970
Mr. Scott L. HowellChief People OfficerN/AN/AN/A
Ms. Elizabeth Van EveryHead of Corporate AffairsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Corporate governance

Vanda Pharmaceuticals Inc.’s ISS governance QualityScore as of 28 February 2024 is 4. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 5; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.